2-乙基-3-羟基环戊-2-烯-1-酮 | 5857-25-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 乙烯基酸
• 中文名称: 2-乙基-3-羟基环戊-2-烯-1-酮
• 英文名称: 2-Aethyl-1,3-cyclopentandion
• 英文别名: 2-Ethyl-1,3-cyclopentandion-enolon；2-ethyl-3-hydroxycyclopent-2-enone；2-Cyclopenten-1-one, 2-ethyl-3-hydroxy-；2-ethyl-3-hydroxycyclopent-2-en-1-one
• CAS: 5857-25-0
• 化学式: C₇H₁₀O₂
• 分子量: 126.155
• InChiKey: RDXQMMNEMFSXDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-乙基-3-羟基环戊-2-烯-1-酮 在 四丁基氟化铵 、 对甲苯磺酸 、 三苯基膦 、 三氟乙酸 、 lithium diisopropyl amide 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 甲苯 、 苯 为溶剂， 反应 30.75h， 生成 4-chloro-N-(3-((3-ethyl-4-isobutoxy-2-oxocyclopent-3-en-1-yl)methyl)phenethyl)benzenesulfonamide
  参考文献：
  名称：

  Cyclopentane-1,3-dione: A Novel Isostere for the Carboxylic Acid Functional Group. Application to the Design of Potent Thromboxane (A2) Receptor Antagonists

  摘要：

  Cyclopentane-1,3-diones are known to exhibit pK(a) values typically in the range of carboxylic acids. To explore the potential of the cyclopentane-1,3-dione unit as a carboxylic acid isostere, the physical chemical properties of representative congeners were examined and compared with similar derivatives bearing carboxylic acid or tetrazole residues. These studies suggest that cyclopentane-1,3-diones may effectively substitute for the carboxylic acid functional group. To demonstrate the use of the cyclopentane-1,3-dione isostere in drug design, derivatives of a known thromboxane A(2) prostanoid (TP) receptor antagonist, 3-(3-(2-(4-chlorophenylsulfonamido)ethyl)phenyl)propanoic acid (12), were synthesized and evaluated in both functional and radioligand-binding assays. A series of mono- and disubstituted cyclopentane-1,3-dione derivatives (41-45) were identified that exhibit nanomolar IC50 and K-d values similar to 12. Collectively, these studies demonstrate that the cyclopentane-1,3-dione moiety comprises a novel isostere of the carboxylic acid functional group. Given the combination of the relatively strong acidity, tunable lipophilicity, and versatility of the structure, the cyclopentane-1,3-dione moiety may constitute a valuable addition to the palette of carboxylic acid isosteres.

  DOI：

  10.1021/jm200980u
• 作为产物：
  描述：

  1,3-环戊二酮 、 乙醛 在 二氢吡啶 、 L-脯氨酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-乙基-3-羟基环戊-2-烯-1-酮
  参考文献：
  名称：

  Cyclopentane-1,3-dione: A Novel Isostere for the Carboxylic Acid Functional Group. Application to the Design of Potent Thromboxane (A2) Receptor Antagonists

  摘要：

  Cyclopentane-1,3-diones are known to exhibit pK(a) values typically in the range of carboxylic acids. To explore the potential of the cyclopentane-1,3-dione unit as a carboxylic acid isostere, the physical chemical properties of representative congeners were examined and compared with similar derivatives bearing carboxylic acid or tetrazole residues. These studies suggest that cyclopentane-1,3-diones may effectively substitute for the carboxylic acid functional group. To demonstrate the use of the cyclopentane-1,3-dione isostere in drug design, derivatives of a known thromboxane A(2) prostanoid (TP) receptor antagonist, 3-(3-(2-(4-chlorophenylsulfonamido)ethyl)phenyl)propanoic acid (12), were synthesized and evaluated in both functional and radioligand-binding assays. A series of mono- and disubstituted cyclopentane-1,3-dione derivatives (41-45) were identified that exhibit nanomolar IC50 and K-d values similar to 12. Collectively, these studies demonstrate that the cyclopentane-1,3-dione moiety comprises a novel isostere of the carboxylic acid functional group. Given the combination of the relatively strong acidity, tunable lipophilicity, and versatility of the structure, the cyclopentane-1,3-dione moiety may constitute a valuable addition to the palette of carboxylic acid isosteres.

  DOI：

  10.1021/jm200980u

文献信息

• Batrachotoxin Analogues, Compositions, Uses, and Preparation Thereof
  申请人：Du Bois Justin

  公开号：US20140171410A1

  公开（公告）日：2014-06-19

  Compounds relating to batrachotoxin are provided, in particular analogues that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier, including vehicles that modulate transdermal permeation of the compound. The subject compounds are useful in treatments, including treatments to reduce neuronal activity or to bring about muscular relaxation. The compounds also find use in the treatment of subjects suffering from a voltage-gated sodium channel-enhanced ailment or from pain. Further methods are provided for the preparation of the batrachotoxin-related compounds.

  提供了与蝙蝠毒素相关的化合物，特别是能够调节钠通道活性的类似物。还提供了包含本发明化合物的药物组合物以及药用辅料，包括能够调节化合物经皮渗透的载体。所述化合物可用于治疗，包括用于减少神经活动或引起肌肉松弛的治疗。这些化合物还用于治疗患有电压门控钠通道增强病症或疼痛的患者。还提供了用于制备与蝙蝠毒素相关化合物的方法。
• Total Synthesis with a Chirogenic Opening Move Demonstrated on Steroids with Estrane or 18a-Homoestrane Skeleton
  作者：Gerhard Quinkert、Michael Del Grosso、Astrid Döring、Wolfgang Döring、Ralf I. Schenkel、Markus Bauch、Gernot T. Dambacher、Jan W. Bats、Gottfried Zimmermann、Gerd Dürner

  DOI：10.1002/hlca.19950780524

  日期：1995.8.9

  A concept of first choice for the synthesis of the title compounds had been proposed by Dane in the late 1930s. It was soon turned down, because the opening move–a chirogenic Diels-Alder reaction – did not work. With Lewis acids as mediators, however, a successful start has been achieved now. With Ti complexes of chelating ligands (Seebach's TADDOLs (= α,α,α′,α′-tetraaryl-1,3-dioxolane-4,5-dimethanols))

  Dane在1930年代后期提出了合成标题化合物的首选方法。很快就被拒绝了，因为开场动作–致色Diels - Alder反应–无效。但是，以路易斯酸为介质，现在已经取得了成功的开始。使用螯合配体的Ti络合物（Seebach 's TADDOLs（=α，α，α'，α'-四芳基-1,3-二氧戊环-4,5-二甲醇）），确实发生了所需加合物的对映选择性形成。已经完成了2和3a的有效总合成。
• [EN] 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS 2-[1-PHÉNYL-5-HYDROXY-4A-SUBSTITUÉS-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ÉTHYL PHÉNYLÉS COMME LIGANDS DES RÉCEPTEURS AUX GLUCOCORTICOÏDES
  申请人：MERCK SHARP & DOHME

  公开号：WO2011053574A1

  公开（公告）日：2011-05-05

  The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖了Formula I的化合物，或其药用可接受的盐或水合物，这些化合物可作为选择性糖皮质激素受体配体，用于治疗各种自身免疫和炎症性疾病或症状。药物组合物和使用方法也包括在内。
• Cycloalkyl-dione Derivatives And Methods Of Their Use
  申请人：Atasoylu Onur

  公开号：US20120329877A1

  公开（公告）日：2012-12-27

  The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; R 1 is H or C 1-6 alkyl and R 2 is H, C 1-6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and X is O or N; as well as tautomers and pharmaceutically acceptable salt forms thereof. Uses of these compounds are also described.

  本发明涉及以下式I的化合物：其中A为0、1或2；m为0或1；R1为H或C1-6烷基，R2为H、C1-6烷基、取代或未取代芳基，或取代或未取代杂环芳基；X为O或N；以及它们的互变异构体和药学上可接受的盐形式。还描述了这些化合物的用途。
• 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
  申请人：Bungard Christopher James

  公开号：US20120214847A1

  公开（公告）日：2012-08-23

  The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖以下化合物：公式I的化合物或其药学上可接受的盐或水合物，其可用作选择性糖皮质激素受体配体，用于治疗各种自身免疫性和炎症性疾病或病况。还包括药物组合物和使用方法。